97802-26-1Relevant academic research and scientific papers
cis- and trans-4-n-propyl-1,2,3,4,4a,5,6,10b-octahydrobenzo(f)quinolines
Cannon,Koble-Suarez,Long,Ilhan,Bhatnagar
, p. 672 - 675 (2007/10/02)
cis- and trans-4-n-Propyloctahydrobenzo(f)quinolines 4a,b were prepared for further assessment of dopaminergic effects of nonoxygenated dopamine congeners. The trans isomer 4b exhibited marked dopamine-like effects in the cat cardioaccelerator nerve assay and in a rat rotation model. Compound 4b produced dose-related lowering of blood pressure in the cat. The cis isomer 4a was inactive in these assays. Both compounds were inactive in a dopamine binding assay, but both appeared active in a spiroperidol binding assay. Both compounds are active α1 and α2-adrenoceptor antagonists. Compound 4b provides evidence that α2-adrenoceptors and dopamine receptors are different entities, since this compound is an α2 antagonist and a dopamine receptor agonist at presynaptic sites.
Synthesis and pharmacology of some 2 aminotetralins. Dopamine receptor agonists
McDermed,McKenzie,Phillips
, p. 362 - 367 (2007/10/05)
A series of 2 amino 1,2,3,4 tetrahydronaphthalene compounds bearing substituents on the nitrogen and in the aromatic ring was synthesized from β tetralone intermediates. Compounds were screened in vivo for dopaminergic activity using tests in which apomorphine was especially active. It was found that apparent dopaminergic activity is inherent in 2 dialkylaminotetralins, the dipropylamine substitution being the most consistently productive amine group studied. Activity was greatly enhanced by proper substitution in the aromatic ring. The 5,6 dihydroxy group was the best potentiating group found. These data support the idea that the extended conformation for the phenylethylamine moiety of apomorphine and dopamine is favorable for dopaminergic agonist activity. They also suggest that an unetherified catechol group may not be essential for such activity.
